ISN-ACT Clinical Trial List: May 2019
ISN Academy. ISN-ACT . May 17, 2019; 272236; 6171 Topic: Global Nephrology
Disclosure(s): The ISN-Advancing Clinical Trials is a new initiative of the ISN intended to leverage existing infrastructures within ISN, in order to improve global nephrology community participation in clinical trial research. As part of its activities, the ISN-ACT highlights and sometimes analyzes important recent nephrology trials from latest medical literature every month through the ISN-ACT Trial-list. Editors of the ISN-ACT Trial-List also select clinical trials of particular impact, and collaborate with the @ISNeducation social media learning team to represent these trials visually. Join the ISN-ACT To generate more high-quality clinical trials and studies in nephrology, ISN-ACT is calling on investigators and interested individuals. If you are an ISN member interested to join this great initiative, submit your application online. Use the button below (download PDF) to download this month's edition of the list.
Login now to access Regular content available to all registered users.

You may also access ISN content "anytime, anywhere" with the FREE ISN Academy App for iOS and Android.
Description
Discussion Forum (0)
Rate & Comment (0)
Once a month, the ISN-ACT (Advancing Clinical Trials) team collects and publishes a list of important nephrology trials from the latest medical literature. Each trial is reviewed in context and their risk of bias in seven key areas assessed.

This month, we reviewed the following trials:

- CREDENCE and the management of diabetic kidney disease
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, et al. N Engl J Med. 2019 Apr 14; doi: 10.1056/NEJMoa1811744

- SONAR study highlights potential of endothelin receptor antagonism in diabetic kidney disease
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
Heerspink, et al. Lancet. 2019 April 15; doi: 10.1016/S0140-6736(19)30772-X

- Direct renin inhibition with imarikiren reduces albuminuria in diabetic nephropathy
Efficacy and Safety of Imarikiren in Patients with Type 2 Diabetes and Microalbuminuria: A Randomized, Controlled Trial
Ito, et al. Clin J Am Soc Nephrol 2019;14(3):354-363

- Ciprofloxacin prophylaxis does not reduce BK viremia after renal transplantation
Ciprofloxacin for BK viremia prophylaxis in kidney transplant recipients: Results of a prospective, double-blind, randomized, placebo-controlled trial
Patel, et al. Am J Transplant. 2019 Feb 27. doi: 10.1111/ajt.15328

- Equivocal result for eculizumab in the prevention of AMR in sensitized kidney transplant recipients
Safety and efficacy of eculizumab in the prevention of antibody‐mediated rejection in living‐donor kidney transplant recipients requiring desensitization therapy: A randomized trial
Marks, et al. Am J Transplant 2019; 1-13. doi: 10.1111/ajt.15364

- Novel acid binding resin raises serum bicarbonate in short term study
Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial
Wesson, et al. Lancet. 2019;393(10179):1417-1427

- Hydroxychloroquine shows promise in IgA nephropathy
Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial
Liu, et al. Am J Kidney Dis. 2019 Mar 25; doi:10.1053/j.ajkd.2019.01.026

- End of the road for high cutoff dialysis in myeloma?
High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial
Hutchison, et al. Lancet Haematol 2019;6:e217–28

- No benefit from spironolactone in patients on hemodialysis
A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients
Hammer, et al. Kidney Int 2019;95(4):983–991

- Beating the blues on hemodialysis: Sertaline may have an edge over CBT
Comparative Efficacy of Therapies for Treatment of Depression for Patients Undergoing Maintenance Hemodialysis
Mehrotra, et al. Ann Intern Med. 2019;170:369-379

- Darbepoetin and erythropoietin appear similarly effective in Indian dialysis recipients
Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial
Sinha, et al. BMC Nephrol 2019;20:90 doi:10.1186/s12882-019-1209-1

- Intestinal phosphate transport inhibition offers novel method of managing hyperphosphatemia
Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial
Block, et al. J Am Soc Nephrol. 2019;30:641–652


A preview of this infographic is available below, and can be downloaded to the left.


 
Code of conduct/disclaimer available in General Terms & Conditions

By continuing to browse or by clicking “Accept Terms & all Cookies”, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies